This page is available in multiple languages
Select Language

EnterNext welcomes Poxel on Euronext in Paris


Thomas Kuhn, CEO of Poxel, rings the opening bell.

Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.

At the end of 2014, the group had 6 products including 1 in phase II of clinical development (Imeglimin), 1 in phase of preclinical development (PXL770) and 4 in research phase.